How Anti-Doping Labs Detect Peptide Drugs in Athletes
Anti-doping labs can detect a wide range of banned peptides — from growth hormone releasers to EPO — but routine testing still lags behind research capabilities.
Quick Facts
What This Study Found
Anti-doping laboratories have developed multiple analytical methods to detect a wide range of peptide drugs in athlete samples. These include chromatographic-mass spectrometric, electrophoretic, immunological, and combined approaches capable of identifying peptides across all molecular sizes.
Low-molecular-weight peptides detected include growth hormone-releasing peptides (GHRPs), ARA-290, TB-500, AOD-9604, CJC-1295, desmopressin, LH-releasing hormones, and synacthen. Intermediate-sized peptides include insulins, IGF-1 and analogs, mechano growth factor, growth hormone, hCG, and erythropoietin. Larger peptides like stamulumab can also be detected.
However, a significant gap remained between what was technically possible in research settings and what could be reliably implemented in routine daily testing of athlete samples.
Key Numbers
Blood, serum, and urine tested · Lower MW peptides: GHRPs, TB-500, AOD-9604, CJC-1295 · Mid MW: insulins, IGF-1, GH, EPO · Higher MW: stamulumab
How They Did This
This is an expert review published in Expert Review of Proteomics that surveys the analytical methods used by anti-doping laboratories to detect peptidic drugs. It covers chromatographic-mass spectrometric techniques, electrophoretic methods, immunological assays, and combined approaches, categorizing detectable peptides by molecular weight.
Why This Research Matters
Peptide doping represents one of the most challenging detection problems in sports drug testing. Unlike traditional small-molecule drugs, peptides are present at extremely low concentrations, are rapidly degraded in the body, and often closely resemble natural human proteins. This review catalogues the state of detection science as of 2014, revealing both the impressive range of peptides that anti-doping labs could identify and the practical limitations preventing comprehensive routine testing.
The Bigger Picture
This review captures a critical period in anti-doping science when peptide use among athletes was rapidly expanding while detection methods were still catching up. Many of the peptides mentioned — TB-500, CJC-1295, AOD-9604, GHRPs — remain popular in underground sports doping and grey-market peptide sales. Since 2014, WADA has expanded its prohibited list and detection methods have improved, but the fundamental challenge of detecting rapidly-degraded, low-concentration peptides in biological samples persists.
What This Study Doesn't Tell Us
As a 2014 review, the detection landscape has evolved significantly with newer mass spectrometry techniques and expanded WADA prohibited lists. The review acknowledges a gap between research-grade detection capability and routine laboratory practice. It does not quantify false positive/negative rates for specific assays.
Questions This Raises
- ?Has the gap between research-grade and routine anti-doping peptide detection been closed since 2014?
- ?How do athletes evade detection given the known capabilities of anti-doping labs?
- ?Are newer peptide drugs being developed faster than detection methods can keep up?
Trust & Context
- Key Stat:
- 15+ peptide classes detectable Anti-doping labs can identify peptides ranging from small GHRPs to large proteins like EPO, though routine testing capabilities lag behind research methods
- Evidence Grade:
- This is a moderate-grade expert review that comprehensively surveys detection methods without conducting new experimental work. It reflects the expert consensus of leading anti-doping analytical chemists.
- Study Age:
- Published in 2014, detection technology and WADA's prohibited list have both expanded significantly since this review. However, the fundamental analytical challenges and many of the peptides discussed remain relevant.
- Original Title:
- Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
- Published In:
- Expert review of proteomics, 11(6), 663-73 (2014)
- Authors:
- Thevis, Mario(8), Thomas, Andreas(7), Schänzer, Wilhelm
- Database ID:
- RPEP-02520
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which peptide drugs can anti-doping labs actually detect?
Labs can detect a wide range including growth hormone-releasing peptides (GHRPs), TB-500, AOD-9604, CJC-1295, various insulins, IGF-1, growth hormone, erythropoietin (EPO), and hCG, among others. Detection uses mass spectrometry, immunological assays, and electrophoretic methods applied to blood, serum, and urine samples.
Why is detecting peptide doping harder than detecting steroid doping?
Peptides are present at much lower concentrations than steroids, they degrade quickly in the body, and many closely resemble proteins the body naturally produces. This makes it harder to prove the substance came from an external source rather than the athlete's own biology.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02520APA
Thevis, Mario; Thomas, Andreas; Schänzer, Wilhelm. (2014). Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.. Expert review of proteomics, 11(6), 663-73. https://doi.org/10.1586/14789450.2014.965159
MLA
Thevis, Mario, et al. "Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.." Expert review of proteomics, 2014. https://doi.org/10.1586/14789450.2014.965159
RethinkPeptides
RethinkPeptides Research Database. "Detecting peptidic drugs, drug candidates and analogs in spo..." RPEP-02520. Retrieved from https://rethinkpeptides.com/research/thevis-2014-detecting-peptidic-drugs-drug
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.